Serina Therapeutics: HC Wainwright Raises Buy Rating, PT to $15.

Serina Therapeutics: HC Wainwright Raises Buy Rating, PT to $15.

Serina Therapeutics' stock experienced a significant surge on August 26, 2025, rising by 28.55% in pre-market trading following the FDA's approval of its SER-252 trial design for advanced Parkinson's disease [1]. The FDA's endorsement enables Serina Therapeutics to proceed under the 505(b)(2) NDA pathway, which accelerates drug development timelines. The company plans to file an Investigational New Drug (IND) application for SER-252 in Q4 2025, marking a crucial step towards initiating clinical trials and bringing the novel therapy closer to market.

In addition to the positive FDA feedback, Serina Therapeutics has also received a boost from financial analysts. HC Wainwright & Co. recently upgraded Serina Therapeutics to a "Buy" rating and raised its price target to $15. The analyst firm cited the company's progress with SER-252 as a key driver behind the upgrade. The move underscores the market's optimism about Serina Therapeutics' potential to make significant strides in treating advanced Parkinson's disease.

The FDA's 505(b)(2) NDA pathway allows for the approval of new drugs based on substantial evidence of safety and effectiveness, which can significantly expedite the drug development process. This pathway is particularly beneficial for companies like Serina Therapeutics that are developing novel therapies for unmet medical needs.

Serina Therapeutics' stock price increase and the analyst upgrade reflect the market's confidence in the company's ability to navigate the regulatory landscape and bring innovative treatments to patients in need. As the company continues to make progress with SER-252, investors will be closely monitoring its clinical trial results and regulatory filings.

References:
[1] https://www.ainvest.com/news/serina-therapeutics-soars-28-55-fda-trial-design-approval-2508/